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Background: Subunit vaccines based on recombinant proteins have been effective in preventing infectious
diseases and are expected to meet the demands of future vaccine development. Computational approach,
especially reverse vaccinology (RV) method has enormous potential for identification of protein vaccine candidates
(PVCs) from a proteome. The existing protective antigen prediction software and web servers have low prediction
accuracy leading to limited applications for vaccine development. Besides machine learning techniques, those
software and web servers have considered only protein’s adhesin-likeliness as criterion for identification of PVCs.
Several non-adhesin functional classes of proteins involved in host-pathogen interactions and pathogenesis are
known to provide protection against bacterial infections. Therefore, knowledge of bacterial pathogenesis has
potential to identify PVCs.
Results: A web server, Jenner-Predict, has been developed for prediction of PVCs from proteomes of bacterial
pathogens. The web server targets host-pathogen interactions and pathogenesis by considering known functional
domains from protein classes such as adhesin, virulence, invasin, porin, flagellin, colonization, toxin, choline-binding,
penicillin-binding, transferring-binding, fibronectin-binding and solute-binding. It predicts non-cytosolic proteins
containing above domains as PVCs. It also provides vaccine potential of PVCs in terms of their possible
immunogenicity by comparing with experimentally known IEDB epitopes, absence of autoimmunity and
conservation in different strains. Predicted PVCs are prioritized so that only few prospective PVCs could be validated
experimentally. The performance of web server was evaluated against known protective antigens from diverse
classes of bacteria reported in Protegen database and datasets used for VaxiJen server development. The web
server efficiently predicted known vaccine candidates reported from Streptococcus pneumoniae and Escherichia coli
proteomes. The Jenner-Predict server outperformed NERVE, Vaxign and VaxiJen methods. It has sensitivity of 0.774
and 0.711 for Protegen and VaxiJen dataset, respectively while specificity of 0.940 has been obtained for the latter
dataset.
Conclusions: Better prediction accuracy of Jenner-Predict web server signifies that domains involved in
host-pathogen interactions and pathogenesis are better criteria for prediction of PVCs. The web server has
successfully predicted maximum known PVCs belonging to different functional classes. Jenner-Predict server is
freely accessible at http://117.211.115.67/vaccine/home.html
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In silico prediction has been proved to be of great signifi-
cance among various disciplines of life sciences including
biomedical research [1]. The conventional vaccine devel-
opment methods are time consuming as they require
cultivation of pathogenic microorganisms in laboratory
conditions and their dissection using microbiological, bio-
chemical and immunological methods in order to identify
the components important for immunogenecity. These
methods are ineffective in circumstances where the culti-
vation of bacteria is difficult or impossible. The other limi-
tations arise when the expression of protective antigens is
less or absent in in vitro conditions compared to in vivo
diseased conditions [2]. In comparison to conventional
live attenuated vaccines, subunit vaccines are more reliable
as far as safety is concerned [3]. Vaccine candidate iden-
tification is an essential and important component in sub-
unit vaccine development. The integration of genomics
in vaccine research (vaccinogenomics) is expected to
revolutionize novel vaccine candidate identification [4].
Computational approach, especially reverse vaccinology
(RV) method assists the identification of vaccine candi-
dates from genomes without culturing microorganisms
and thus facilitates the subunit vaccine development.
These methods are useful in reducing time, cost and num-
ber of wet lab experiments [2].
The RV is a computational pipeline for identification of
vaccine candidates against microorganisms from their
genome sequences. Thus, all proteins of an organism can
be screened computationally for their vaccine potential.
Significant success of this principle for vaccine develop-
ment had already been demonstrated in several pathogens,
including Neisseria meningitides [5], Helicobacter pylori [6],
Streptococcus pneumoniae [7], Porphyromonas gingivalis
[8], Chlamydia pneumoniae [9] and Bacillus anthracis [10].
The relevance of this method was recognized when
vaccines developed from capsular polysaccharides of N.
meningitides B failed due to cross reactivity against human
tissue [5]. Application of RV techniques for PVC identifi-
cation and then in vivo testing led to the development of
licensed broad specificity protein vaccine, 5CVMB, against
N. meningitides. This vaccine contains 5 protein antigen
components, GNA2132, GNA1870, GNA1030, GNA2091
and NadA, which were primarily discovered by RV
methods [11]. However in earlier RV techniques, protein
localization (secretory, outer-membrane, transporter or
others) was used as the main criterion for identification
of PVCs. As a result, a large number of proteins were
required to be expressed, purified and tested to obtain
few vaccine candidates leading to enormous loss of cost
and time.
On the other hand, identifying immunogenic proteins
(PVCs) by using epitope prediction software and web
servers have several limitations. Comparative studies haveshown that B-cell epitopes (BCEs) and class-II MHC-
binding T-cell epitopes (TCEs) prediction methods are not
accurate [12-15]. Over-prediction, inability in exact pos-
ition prediction of epitopes and absence of success in
identifying known epitopes in proteins are major concerns
in vaccine candidate identification. Until now the available
PVCs prediction software and web servers have not been
much effective for identification of vaccine candidates
from genomes for vaccine design. VaxiJen server, based on
discriminant analysis and partial least square (DA-PLS)
methods, was developed by using datasets of known (posi-
tive) protective antigenic and non-antigenic (negative)
proteins to predict PVCs [16]. Surprisingly, it predicts
more than half of proteins from a given bacterial prote-
ome as protective antigens with default parameters mak-
ing its usage almost impractical. Further, existing software
and web servers predict different proteins as vaccine
candidates from same proteome sequences. For example,
different proteins were predicted from S. pneumoniae
proteome by VaxiJen [16] server and new enhanced re-
verse vaccinology environment (NERVE) [17] software.
From 2202 proteins of S. pneumoniae, VaxiJen (with cut-
off of 0.6) and NERVE predicted 313 and 58 as PVCs, re-
spectively while only 20 proteins were common between
them. None of the common PVCs matched with 18
known vaccine candidates in S. pneumoniae (Additional
file 1: Table S1). This outcome complicates decision
process regarding which tool’s output should be taken for
experimental testing to identify vaccine candidates.
The method used in NERVE [17] and Vaxign [18] tools
presumed that extracellular proteins having adhesin-
likeliness are potential vaccine candidates. Although
adhesin-likeliness of a protein is an important criterion, it
should not be considered as the only one because several
non-adhesin functional classes of proteins (i.e. invasin,
porin, flaggelin, etc.) are also involved in host-pathogen
interactions or pathogenesis and many of them are known
to be antigenic [19-31]. It has been suggested that
targeting host-pathogen interactions and disease processes
at molecular level can be used for novel vaccine discovery
[4]. In several cases, the immune responses against these
non-adhesins were known to provide protection against
microbial infection [19-31]. Invasin, porin, flagellin and
toxin have roles in host cell invasion [32]; transportation
activity is associated with pathogenesis and virulence [33];
chemotaxis, adhesion and colonization are making patho-
genic bacteria to be virulent [34]; and host cell death [35],
respectively. Bacterial fibronectin-binding proteins (FBPs)
target host fibronectin for adhesion and colonization [36];
transferrin-binding proteins (TBP) are used by bacteria to
obtain iron directly from host transferrins [37]; and
penicillin-binding proteins (PBPs) are involved in peptido-
glycan biosynthesis to maintain cell wall structure and
protection [38]. The solute binding proteins (SBPs) are
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onment devoid of free nutrients within the host [21].
Choline-binding proteins (CBPs) in some bacteria perform
adhesin-like function [39]. Functional classes of proteins
involved in virulence [26], invasion [23] and colonization
[29]; porins [22] and flagellin [28]; and binding proteins of
choline [20], penicillin [27], transferrin [25], fibronectin
[24] and solute [21] are important in host-pathogen inter-
actions and pathogenesis. Since many proteins from these
functional classes provide protective immune responses
against microbial infection [19-31], the knowledge of host-
pathogen interactions related to bacterial pathogenesis
could be used to rationalize and improve vaccine candi-
date prediction.
A web server, Jenner-Predict, has been developed which
is capable of predicting PVCs from proteome/protein se-
quences. It is based on the principle that non-cytosolic
proteins having functions (domains) important in host-
pathogen interactions and/or pathogenesis are potential
vaccine candidates (Figure 1). It has two broad compo-
nents: PVCs prediction and analysis of their vaccine
potential. The PVCs prediction is performed in threeFigure 1 Flow chart depicting pipeline of Jenner-Predict server.sequential steps: prediction of subcellular localization,
expressibility in laboratory and presence of domains
critical in host-pathogen interactions and pathogenesis.
Software PSORTb 3.0 is used for protein subcellular
localization prediction [40]. A protein has high probability
of failure to express in experiment [5] when it has more
trans-membrane helices. HMMTOP 2.0 [41] software is
used for topology prediction and proteins with more
than two trans-membrane helices are discarded. Pro-
teins pass through above two filters, and having
domains involved in host-pathogen interactions and
pathogenesis from functional classes of adhesin, invasin,
toxin, porins, colonization, virulence, flagellin, penicillin-
binding, choline-binding transferring-binding, fibronectin-
binding and solute-binding proteins are selected as
vaccine candidates. Standalone Pfam sequence search is
used for prediction of domains [42]. Vaccine potential of
PVCs is predicted on the basis of their possible immuno-
genicity, absence of autoimmunity, and conservation
across different pathogenic and non-pathogenic strains of
same bacteria. Known BCEs and TCEs from immune epi-
tope database (IEDB) [43] are mapped separately on
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gion and potential. This mapping of antigenic determinant
(epitope) is instrumental in predicting humoral (BCE) or
cellular (TCE) or both immune responses of PVC. Since
PVCs specific to pathogenic strains are expected to be in-
volved in virulence [26], therefore conservation of PVCs
in different pathogenic strains of same organism is deter-
mined to provide more robust vaccine candidates. The
PVCs having homolog(s) in host (human) are provided by
the web server. Such PVCs may produce autoimmunity
[44] or less immune response [45]. Taking into account
above criteria, output of the web server is provided as pri-
oritized PVCs in the result table. Comparison among PVC
prediction methods has shown that Jenner-Predict server’s
performance is better.
Results
The web server, Jenner-Predict, has been developed to
predict PVCs from proteome or protein(s) sequences for
subunit vaccine development on the basis of domains
critical to host-pathogen interactions and pathogenesis.
Besides predicting PVCs, it also furnishes information
crucial to determine their vaccine capability in terms of
immunogenic potential by matching PVCs against IEDB
epitopes, autoimmunity through matching PVCs with
human proteome, and their conservation across different
pathogenic and non-pathogenic strains of the organism
(Additional file 2: Figure S1). A tutorial explaining how
to submit a job as well as user-friendly interpretation of
results is available at the web server’s home page. The
web server gives higher priority to PVCs containing
more IEDB epitope matches as they increase their possi-
bility to be immunogenic. The PVCs containing exact
IEDB epitopes match are shown in white background. The
web server also decreases priority of PVCs having human
homologs as such PVCs should be discouraged from fur-
ther vaccine development process. This prioritization is
instrumental in selecting few PVCs for further vaccine de-
velopment experiments. The performance of the web ser-
ver was evaluated against reported vaccine candidates in
S. pneumoniae (gram positive) and E. coli (gram negative),
proteins {both positive (protective antigen) and negative
(non-antigen)} used for the development of VaxiJen server
[16] and protective antigens from more than 40 bacteria
reported in Protegen database [46].
PVCs Prediction in S. pneumoniae and E. Coli
In S. pneumoniae proteome, Jenner-Predict server pre-
dicted 69 proteins as vaccine candidates (Additional file 3:
Table X1). As VaxiJen server predicts more than half of a
proteome as vaccine candidates in any bacteria with de-
fault VaxiJen probability score, 0.4, a cut-off of 0.6 was
considered to restrict the number of PVCs so that the per-
formance of this approach can be compared against allother methods. From S. pneumoniae proteome, our web
server predicted 10 out of 18 known non-cytoplasmic
PVCs whereas the software, NERVE, and servers, Vaxign
and VaxiJen, predicted only 7, 6 and 3 PVCs, respectively
(Additional file 1: Table S1). As compared to other
methods, the PVCs predicted exclusively by Jenner-
Predict server were STK [47], NanA [23], and PsaA [48]
that are having PASTA, BNR, and SBP domains, respect-
ively (Additional file 1: Table S1). Other than 10 reported
vaccine candidates from 69 PVCs (Additional file 3: Table
X1), our web server predicted 18 ABC-transporters and
solute-binding, 6 choline-binding, 4 penicillin-binding, 2
LysM-containing domain, 3 cell wall anchors, etc. ABC-
transporter [49], choline-binding [20] and penicillin-
binding [27] proteins are known to be potential PVCs in
different bacteria including S. pneumoniae.
In E. coli proteome, Jenner-Predict server predicted 253
proteins as vaccine candidates (Additional file 4: Table X2)
whereas the NERVE and VaxiJen predicted more than 500
and 280 proteins, respectively. Our web server predicted
23 out of 28 known PVCs whereas software, NERVE
and servers, Vaxign and VaxiJen, predicted 21, 18 and
21 PVCs, respectively. The PVCs missed out by other
methods due to being non-adhesins were OmpA
(outer-membrane protein A), BtuB (cobalamin outer-
membrane transporter), TolC (channel protein) and
IreA (putative iron-regulated outer membrane virulence
proteins) (Additional file 5: Table S2). Besides 23 known
protective antigens, the majority of predicted PVCs by
our web server were 51 BPD transporter proteins, 32
solute-binding proteins [21] and 32 fimbrial proteins
[50] (Additional file 4: Table X2).
Prediction of PVCs against protegen database and
datasets used in VaxiJen server development
The results of our web server for prediction of known
protective vaccine candidates from more than 40 diverse
bacteria reported in Protegen database and its compari-
son against other similar methods has been presented in
Additional file 6: Table S3. Our web server predicted
137 out of 177 protective antigens (Refer ‘Collection of
data for web server validation’ subsection in Methods)
from Protegen database whereas software, NERVE, and
servers, Vaxign and VaxiJen, predicted 121, 89 and 97,
respectively. The protective antigens (PAs) which were
only predicted by our method and skipped by others
(NERVE, Vaxign and VaxiJen) belong to functional classes
of solute binding, toxin, invasin, etc. (Additional file 6:
Table S3). The Jenner-Predict server was found to be ef-
ficient in discriminating between antigens and non-
antigens. From the 83 PAs (positive dataset) used in
VaxiJen server development, NERVE, Vaxign and
VaxiJen predicted 53, 47 and 46 proteins, respectively
whereas our web server predicted 59 PVCs (Additional
Jaiswal et al. BMC Bioinformatics 2013, 14:211 Page 5 of 11
http://www.biomedcentral.com/1471-2105/14/211file 7: Table S4 (A)). From negative dataset (considered
as non-antigens) of 33 proteins, the NERVE, Vaxign and
VaxiJen methods predicted 8, 5 and 3 proteins to be
vaccine candidates, respectively compared to 2 proteins
(Q48919 and Q53247) by our web server (Additional file 7:
Table S4 (B)). Negative dataset proteins were considered
as non-antigens. But one out of two PVCs predicted by
our web server has already been known to be anti-
genic: fibronectin-attachment protein (Q48919) provides
protective immunity against Mycobacterium avium
infection [51].Validation of Jenner-predict
Sensitivity and specificity indices of different PVC pre-
diction methods have been presented in Table 1. Jenner-
Predict server’s PVCs prediction accuracy is better at all
levels: bacterial proteomes, Protegen database and
datasets used for VaxiJen server development. Unavail-
ability of total number of known vaccine candidates in a
proteome prevented us to calculate sensitivity and spe-
cificity values for proteome sequences. The results of
PVC prediction from two proteomes by different
methods have been provided in Table 1. Detailed com-
parison of results w.r.t known vaccine candidates of S.
pneumoniae and E. coli by different methods has been
provided in Additional file 1: Table S1 and Additional
file 5: S2, respectively. On dataset used in development
of VaxiJen server, sensitivity and specificity of our tool
were 0.711 and 0.940, respectively whereas comparable
methods NERVE, Vaxign and VaxiJen have correspond-
ing values 0.639 and 0.765; 0.494 and 0.853 and 0.554
and 0.909, respectively. For the Protegen database, only
sensitivity was calculated as specificity calculation was
not feasible due to lack of negative dataset. The sensitiv-
ities of NERVE, Vaxign and VaxiJen were 0.684, 0.491
and 0.548, respectively as compared to 0.774 for Jenner-
Predict server.Table 1 Performance evaluation of Jenner-Predict server agai
and VaxiJen*
S.
No.
Different
software and
web servers
Prediction in Prediction in $Protegen (bacter
S. pneumoniae# E. coli# No of predictions
1. NERVE 7 (18) [58] 21 (28) [527] 121 (177)
2. Vaxign 6 (18) [61] 18 (28) [286] 89 (177)
3. VaxiJen 3 (18) [313] 21 (28) [955] 97 (177)
4. Jenner-Predict 10 (18) [69] 23 (28) [253] 137 (177)
* See method section for details.
# Values within square bracket indicates total number of proteins vaccine candidate
indicates experimentally known protective vaccine candidates in that organism wh
software/server from experimentally known protective vaccine candidates in that o
$ Values indicate the number of PVCs predicted by respective software/server from
% Values indicate the number of PVCs predicted by respective software/server fromDiscussion
The motivation behind developing ‘Jenner-Predict’ web
server is to provide credible vaccine candidates and infor-
mation regarding their vaccine potential in terms of pos-
sible immunogenicity, absence of autoimmunity and
conservation so that subunit vaccine development can be
accelerated. The outcome of the web server has substanti-
ated that domains involved in host-pathogen interactions
are better criterion for prediction of PVCs than ap-
proaches dependent upon only adhesin-likeliness or ma-
chine learning. As PVCs are predicted based on their
functions, biologists can assess the importance of a given
function in pathogenesis for that organism. The informa-
tion regarding the function of PVC could be instrumental
for vaccine development. For example, colonization is cru-
cial in Streptococcus pathogenesis and proteins (also pre-
dicted by Jenner-Predict) involved in this process were
used as vaccine candidates [52].
Most of the earlier RV methods focused on outer
membrane or secretory proteins of a proteome to iden-
tify PVCs. Pizza et al. screened proteome sequences of
N. meningitis to identify proteins which were probably
surface exposed or involved in transportation and
obtained 570 proteins. Out of them, 350 proteins were
expressed and experimentally tested for their immuno-
genic potential. Finally, 7 proteins were found to provide
protective immunity against N. meningitides [5]. Simi-
larly, Wizemann et al. searched for motifs related to
secretory or surface binding proteins in S. pneumoniae
proteome and identified 130 proteins containing such
motifs. Out of them, 108 were expressed and tested for
their protective immunity. Finally, 6 proteins were found
as protective antigens. Similar studies were performed
for P. gingivalis [8] and C. pneumoniae [9]. Although
proteins providing immunity were identified in these
studies but the number of experiments, cost and time
requirement were enormous even for identifying PVCs
from a particular localization. On the contrary, Jenner-nst existing software, NERVE, and web servers, Vaxign
ial) %Data used for VaxiJen server development
Sensitivity Positive data Negative data Sensitivity (Specificity)
0.684 53 (83) 8 (33) 0.639 (0.758)
0.502 41 (83) 5 (33) 0.494 (0.848)
0.548 46 (83) 3 (33) 0.554 (0.909)
0.774 59 (83) 2 (33) 0.711 (0.940)
s (PVCs) predicted by respective software/server. Value within parenthesis
ereas the values in bold give the number of PVCs predicted by respective
rganism.
177 bacterial protective antigens (PAs) taken for evaluation.
83 and 33 proteins for positive and negative datasets, respectively.
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host-pathogen interactions for providing reasonably less
number of prioritized vaccine candidates from a prote-
ome. For better validation of vaccine candidates, the
user may select few prospective vaccine candidates for
experimental testing to verify their protective immunity.
The BCE and TCE mapping algorithms were developed
to identify possible immunogenic region(s) and conse-
quently prediction of immunogenic potential of a protein.
But these methods have drawbacks of over-prediction and
even predict epitope(s) in known non-antigenic proteins
[12-15]. Currently available antigen or PVC prediction
methods were not validated on complete or diverse data.
NERVE software was evaluated on its prediction ability of
popular vaccine candidates from five bacterial proteomes
instead of all known vaccine candidates in those organ-
isms. Similarly, the Vaxign server was evaluated against
only limited number of known outer membrane protein
(OMP) vaccine candidates from uropathogenic E. coli
[18]. Further, the VaxiJen server was developed on limited
data. Even some of the sequences used as the negative data
(non-antigenic) for web server development were pre-
dicted as vaccine candidates (antigenic proteins) by all
other methods (Additional file 7: Table S4 (B)). Our web
server predicted two such proteins (Q48919 and Q53247)
as PVCs from the negative dataset sequences. Experimen-
tal data confirmed that alanine and proline rich secreted
protein (Q48919) is immunogenic [51] whereas the other
protein (Q53247) is a periplasmic serine or membrane
protease (htrA gene) and has already been reported as
protective antigen in Haemophilus influenzae [53]. The
other PVCs predicted from negative dataset by NERVE,
Vaxign and VaxiJen have no evidence of being immuno-
genic. This outcome justifies higher sensitivity of our
method.
To provide prospective PVCs of a proteome, the pre-
dicted vaccine candidates are prioritized by Jenner-
Predict server. The PVCs having more IEDB epitope
matches are ranked higher as such epitope match in-
creases their possibility to be immunogenic. Epitopes
identified using ‘hands on’ peptide-by-peptide in vitro
assays as in case of immunoepitope database have been
more substantive than epitopes predicted by using in
silico methods. Therefore, known and validated epitopes
from the IEDB [43] are mapped on PVCs to predict po-
tential immunogenic regions. The Jenner-Predict server
de-prioritizes PVC having human homolog(s) as they
can potentially cause autoimmunity [44] or produce low
immune response [45]. Conservation information of
PVCs is provided by the web server to demonstrate their
broad specificities. Since the web server provides con-
served and potential immunogenic PVCs, it may be
useful to replace the existing strain-specific vaccine can-
didates. For example, the established vaccine candidate,PspA is having choline-binding protein (CBP) domain
and it has limited application from vaccine point of view
as it is strain-specific. In contrast, our tool predicted
cbpE (gi|225858728) protein which is conserved across
different strains of S. pneumoniae and has the same CBP
domain. Since this protein is surface exposed, and in-
volved in nasopharyngeal colonization and/or dissemin-
ation of S. pneumoniae which is important for virulence,
this protein may further be explored for vaccine devel-
opment process [39].
Jenner-Predict server predicted 3 experimentally known
promising PVCs, STK [47], NanA [23], and PsaA [48]
in S. pneumoniae which are containing domains from
non-adhesins such as PASTA, BNR and SBP, respectively
(Additional file 1: Table S1) and they are known to be im-
munogenic. Similarly, our method predicted established
non-adhesin vaccine candidates, Omp A, IreA, BtuB and
TolC (provides protective immune responses [54] in E.
coli). The wide-ranging applicability of the web server to
all bacteria is substantiated by its high sensitivity for
predicting diverse protective antigens from more than
40 pathogenic bacteria reported in Protegen database
(Additional file 6: Table S3) and dataset used for VaxiJen
server development (Additional file 7: Table S4). Our do-
main based method was effective in predicting many
established non-adhesin vaccine candidates reported in
Protegen database [46] such as 13 toxins, 12 binding pro-
teins (fibronectin, penicillin, choline, etc.), 10 membrane
proteins, 6 surface proteins, etc. (Additional file 6: Table
S3) which were not predicted by other methods. These
protective antigens are involved in many important patho-
genesis processes like virulence, invasion, colonization,
iron acquisition, osmo-regulation, etc. (Additional file 6:
Table S3). The sensitivity of the web server was further
substantiated by its prediction of immunogenic protein,
Q48919, from negative dataset used for training of VaxiJen
server (Additional file 7: Table S4 (B)). Higher sensitivity
and specificity of Jenner-Predict server (Table 1) justifies
the domains involved in host-pathogen interactions and
pathogenesis are better criteria for PVCs prediction than
other existing approaches.
Conclusions
The Jenner-Predict server has been developed to predict
potential PVCs and to provide their vaccine potential with
an objective of assisting subunit vaccine development. The
web server was validated on independent and diverse
datasets, where it outperformed other PVC prediction
tools. Its performance substantiated that the proteins in-
volved in host-pathogen interactions and pathogenesis are
better criteria than methods based on machine learning or
adhesin-likeliness. Our method predicts less number of
proteins with high prediction accuracy which confirms its
reliability. Mapping of known epitopes from IEDB database
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munogenic. Comparison of these PVCs with human
proteome sequences reduces the chance of their failure
due to autoimmunity. Conservation of PVCs in patho-
genic strains provides crucial information on their
broad-specificities. The web server demonstrated that
domain-based method can be used to predict PVCs
from pathogen proteomes. Since the web server pro-
vides prioritized PVCs, few prospective proteins from a
proteome could be taken for experimental evaluation to
identify subunit vaccine candidates.Methods
Data collection and generation
Proteomes of all bacteria were downloaded from NCBI ftp
(ftp://ftp.ncbi.nih.gov/genomes/Bacteria/all.faa.tar.gz). The
proteomes of S. pneumoniae strain 70585 and Escherichia
coli uropathogenic strain CFT073 were collected from
above proteomes. Human proteome sequences were
downloaded from the EBI ftp site (ftp://ftp.ebi.ac.uk/pub/
databases/integr8/fasta/proteomes) for prediction of hu-
man homologs in PVCs. For the development of web ser-
ver, standalone version of four softwares (Additional file 2:
Figure S1), NCBI BLAST (ftp://ftp.ncbi.nlm.nih.gov/blast/
executables/blast+/LATEST/), PSORTb 3.0 (http://www.
psort.org/psortb/), HMMTOP 2.0 (http://www.enzim.hu/
hmmtop/) and HMMER 3.0 (http://hmmer.janelia.org/)
were downloaded from their respective websites. PSORTb
3.0 predicts subcellular localization of a given protein se-
quence based on its amino acid composition, similarity to
proteins of known localization, and presence of different
motifs and signal peptides [40]. HMMTOP software uses
hidden Markov model (HMM) to predict transmembrane
helices based on the difference in the amino acid distribu-
tions in various structural parts of proteins [41]. For pre-
diction of domains in protein sequences, Perl program,
pfam_scan.pl and Pfam library of HMMs for protein fam-
ilies were downloaded from Pfam website (http://pfam.
janelia.org/).
For prediction of immunogenic regions in PVCs, ex-
perimentally known immunogenic epitope sequences of
all T-cell epitope (TCE) and B-cell epitope (BCE) assays
were downloaded from IEDB (http://www.iedb.org/) in
CSV format. Peptide epitope with literature reference,
epitope ID, GI of source protein, and source and host
organism’s information were extracted from these TCEs
and BCEs assays. In case of TCEs, MHCs allele names
were also extracted. All epitope sequences were stored
in ‘fasta’ format for comparison against PVCs. For dis-
continuous BCEs, corresponding protein sequences were
downloaded from database, and stretch of continuous
sub-part protein sequences containing all the residues of
discontinuous epitope positions was extracted. Thesesubsequences (epitopes) were also stored in ‘fasta’ format
for comparison against predicted PVCs.Collection of data for web server validation
Experimentally known protective antigens were collected
from four diverse sources to evaluate the performance of
Jenner-Predict server against existing methods. Known
non-cytosolic protective PVCs from the two pathogenic
bacteria, S. pneumoniae (gram-positive) and E. coli (gram-
negative) were collected from literature. Different experi-
ments had identified 18 and 28 non-cytosolic proteins to
be protective antigens for S. pneumoniae and E. coli, re-
spectively (Additional file 1: Table S1 and Additional file 5:
Table S2). To demonstrate effectiveness of the web server
in predicting vaccine candidates across bacteria, non-
cytosolic protective antigens sequences reported in
‘Protegen’ database [46] were retrieved for evaluation as
well. Out of the 257 reported bacterial protective PVCs in
Protegen database, 211 were predicted to be non-cytosolic
by PSORTb 3.0. After removing 11 antigens having more
than 2 trans-membrane helices and sequences which are
90 percent identical among themselves by using CD-HIT
(http://weizhong-lab.ucsd.edu/cd-hit/ref.php), 177 bacter-
ial protective PVCs were selected for evaluation. In
addition to above, non-cytosolic proteins from datasets
used for VaxiJen [16] server development were also taken
for evaluation. Positive and negative training and test
datasets containing 100 sequences of each in the form of
Swiss-Prot IDs were collected and then their sequences
were retrieved. PSORTb was used to predict their
localization and only non-cytosolic proteins were retained.
Finally, 83 and 33 non-cytosolic positive (protective anti-
gen) and negative (non-antigen) sequences were selected
for comparison of performances. The sequences used for
validation in both Protegen and VaxiJen datasets are
highly diverse (more than 90% sequences are less than
40% identical).Server architecture
The web server comprised of a client interface and a
main application program. The client interface was de-
veloped using HTML language which takes input either
in the form of protein sequence(s) in fasta format or a
proteome of listed bacteria. The submitted fasta se-
quence(s)/proteome are processed by the in-house
backend Perl-CGI script which posts information pro-
vided by the user to the main application program in a
queue. This Perl-CGI script generates an URL link
where the status information or output of a given job
will be available. The self developed programs and other
available standalone software (Figure 1) are used by
‘main application’ program for the analysis of protein se-
quences one after another to predict PVCs. The main
Figure 2 Sample output of Jenner-Predict server.
Table 2 Key words used and selection of Pfam domains
for protein vaccine candidate prediction
Sr.
No.
Key word used for
PFam domain search
No of
domain
hits
No of
selected
domains*
Reference
1. Adhesin 166 96 19
2. Choline binding protein 29 12 20
3. Bacterial extracellular
solute-binding protein
36 8 21
4. Porin 66 46 22
5. Invasin 30 25 23
6. Fibronectin-binding
protein
50 25 24
7. Transferrin-binding
protein
24 6 25
8. Virulence 402 145 26
9. Penicillin-binding
Protein
14 8 27
10. Flagellin 22 12 28
11. Colonization 23 14 29
12. Host-pathogen
interaction
9 4 30
13. Toxin 542 110 31
*Only those families/domains were included which are involved in host-
pathogen interactions and/or pathogenesis.
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prioritized PVCs.
Pfam domain identification
Domains are basic building blocks of proteins. Searching
of a protein sequence against Pfam library of HMMs en-
ables to find domain architecture present in that protein
[42]. The Pfam has been used in several genome projects
including human for large scale functional annotation of
genomic data [55]. A list called, ‘Master list’, was prepared
which contains Pfam IDs (domain) from the functional
classes of proteins involved in host-pathogen interactions
and pathogenesis [19-28]. For preparing the list, Pfam
database was subjected to text search with individual key
words ‘adhesin’, ‘choline binding protein’, ‘bacterial extracel-
lular solute-binding protein’, ‘porin’, ‘invasin’, ‘fibronectin-
binding protein’, ‘transferrin-binding protein’, ‘virulence’,
‘penicillin-binding protein’, ‘flagellin’, ‘colonization’, ‘host-
pathogen interaction’ and ‘toxin’ to identify domains from
each classes of proteins. Then all hits of domains from
each keyword were manually checked for their possible
role in host-pathogen interactions. Only those families/do-
mains were included in the ‘Master list’ which have signifi-
cant functional role in host-pathogen interactions and/or
pathogenesis (Table 2). This ‘Master list’ of domains was
used for the prediction of PVCs from non-cytosolic
proteins.
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The server, Jenner-Predict, has two major components:
PVCs prediction and analysis of their vaccine potential
(Figure 1 and Additional file 1: Figure S1). In first com-
ponent, software PSORTb 3.0 [40] and HMMTOP 2.0
[41] are used to predict subcellular localization and
number of transmembrane helices, respectively. The
former discards cytoplasmic proteins whereas the latter
rejects proteins having more than two transmembrane
helices [5]. Proteins passing through the above two fil-
ters are then subjected to Pfam domain/family search to
determine their domains. Finally, role of identified do-
mains in host pathogen interaction and pathogenesis is
checked according to its presence in ‘Master list’ (de-
scribed in ‘Pfam Domain Identification’ subsection and
Table 2). Proteins having domains/families matching
with Pfam domains/families listed in the ‘Master list’ are
selected as PVCs.
In second component, vaccine potential of the predicted
PVCs’ is performed by taking three different measures into
account (Figure 1): immunogenicity, autoimmunity and
conservation. Immunogenic potential (putative immuno-
genic regions in terms of BCEs and TCEs) of PVCs is pre-
dicted by exactly matching of IEDB epitopes (Refer ‘data
collection and generation’ subsection) against the PVCs by
using standalone BLAST with minimum matching length
of 9 [56] and 80% identity cut-off. For autoimmunity pre-
diction, the BLAST is used to find similarity between
PVCs and human proteins by two different methods: i)
cut-off of 35% identity in at least 80 amino acids length of
PVC [57], and ii) continuous identical matching of 9 or
more positions in the alignment [56]. BLAST is also used
to identify conservation of PVCs in different pathogenic
strains of a given organism. The PVC is compared against
different strains of the same organism with a cut-off
greater than 85 percent sequence identity with minimum
of 90% query coverage. To determine conservation of
PVC in pathogenic and non-pathogenic strains separately,
names of pathogenic and non-pathogenic strains of each
organism are stored in two separate flat files under each
category. Information on pathogenic or non-pathogenic
strains of each individual organism is extracted from the
respective files.
Output
The server, Jenner-Predict, has been designed for easy sub-
mission of a job as well as user-friendly interpretation of
results. Just after job submission, an URL link is generated
which the user may bookmark for tracking the jobs status
which is processed in a queue. Once a job has been com-
pleted, the output is provided in a tabular format and a
sample output is represented in Figure 2. The information
provided in different columns are as follows: 1. Sr. No.; 2.
Gene Id; 3. Localization; 4. No. of transmembrane helices;5. Pfam domain ID; 6. No. of IEDB TCE(s) match(s); 7.
No. of IEDB BCE(s) match(s) (Hyperlinks on 6 and 7
showing details of matching epitopes); 8. and 9. Auto-
immunity information through 35% identical matches in
80 AA lengths, and No. of continuous 9-mer identical
match in an alignment, respectively; and 10. Conservation
in number of strains of an organism in the form of x/y/z:
x. all (pathogenic and non-pathogenic)/, y. pathogenic/, z.
non-pathogenic.
Additional files
Additional file 1: Table S1. Comparison of results for predicted protein
vaccine candidate (PVC) by software, NERVE, and web servers, Vaxign,
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(gram positive).
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